Moderna Says Higher Efficacy Was Observed In mRNA-1283 Compared To Spikevax In Adults 18 Years Of Age And Older
Portfolio Pulse from Benzinga Newsdesk
Moderna announced that its new vaccine, mRNA-1283, has shown higher efficacy compared to its existing Spikevax in adults aged 18 and older. The Phase 3 trial met its primary efficacy endpoint.
June 13, 2024 | 11:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's new vaccine, mRNA-1283, has demonstrated higher efficacy compared to Spikevax in adults aged 18 and older, meeting its primary endpoint in Phase 3 trials. This positive development could boost investor confidence and potentially drive the stock price up in the short term.
The announcement of higher efficacy for mRNA-1283 compared to Spikevax is a significant positive development for Moderna. Meeting the primary endpoint in Phase 3 trials suggests strong potential for the new vaccine, likely increasing investor confidence and driving the stock price up.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100